Valganciclovir hydrochloride CAS NO.175865-59-5

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Valganciclovir is a DNA polymerase inhibitor. After oral administration, it is rapidly hydrolyzed into ganciclovir under the action of intestinal mucosal cell esterase and liver esterase, so its pharmacodynamic properties are that of ganciclovir. Ganciclovir produces ganciclovir triphosphate under the phosphorylation of enzymes in the virus and Chemicalbook cells. The latter competes with deoxyguanosine triphosphate (dGTP) as a substrate for viral DNA polymerase, thereby inhibiting viral DNA synthesis , Thereby producing anti-CMV activity.

It is used to prevent and treat CMV infection secondary to organ transplantation. The drug is a prodrug of ganciclovir (ganciclovir), which is an active ganciclovir valine ester. After oral administration, it can be quickly dissolved into ganciclovir by phosphatase in the intestinal and liver cells. Its antiviral spectrum and mechanism of action are similar to ganciclovir, but its bioavailability is significantly higher than ganciclovir. Its oral absorption bioavailability is 62.4%, which is 10% of ganciclovir. Times, but the toxicity is greatly reduced.

Valganciclovir hydrochloride is an L-valyl ester hydrochloride of ganciclovir, which exists as a mixture of two diastereomers. After administration, these diastereomers are rapidly converted to ganciclovir by esterases in the liver and intestines. In cells infected with macrophages (CMV), ganciclovir is first phosphorylated by viral protein agent kinases to generate monophosphate forms, and then further phosphorylated by cellular kinases to generate triphosphate forms. The triphosphate is slowly metabolized in the cell. The Chemicalbook process of phosphorylation is dependent on viral kinases and occurs preferentially in virus-infected cells. Ganciclovir inhibits virus activity because ganciclovir triphosphate inhibits viral DNA synthesis. Ganciclovir triphosphate integrates into the DNA strand to replace many adenosine bases. This hinders DNA synthesis, and phosphodiester bonds take longer to form, thereby weakening the stability of the chain. Ganciclovir inhibits viral DNA polymerase more effectively than cellular polymerase. When ganciclovir is removed, chain extension restarts